Felix Health Launches Generic Semaglutide starting at $149/Month - What Canadians Need to Know

A few things from sources close to Felix's launch that have not surfaced widely yet - including demand signals, why Apotex was chosen as the first supplier, and how low Canadian pricing could realistically go.

The Waitlist Tells the Real Story

Felix opened a generic semaglutide waitlist back in December 2025, anticipating that generic versions would enter the Canadian market in early 2026. The list filled to about 4,000 patients and sat there for months.

In the last two to three weeks, it grew to nearly 15,000.

That is roughly 11,000 additional waitlist signups in just three weeks. According to information from sources familiar with Felix's operations, that spike is a direct demand signal worth paying attention to:

“It just highlights cost really is a barrier for a lot of patients. That spike is a really interesting indicator of how patients have been waiting for this change in price - and for the removal of this barrier to accessibility.”

It also helps explain the level of demand Felix is seeing at launch.

What $149 Actually Buys You

The $149/month price includes the medication and free delivery. The assessment fee covers:

• Ongoing access to a healthcare provider team for clinical questions
• Support around dose titration and side-effect management
• Injection trackers and 24/7 chat with the care team

Patients submit an application and are evaluated for prescription approval by a licensed Canadian healthcare practitioner. If approved, you choose where to have your prescription filled - Felix's pharmacy or the pharmacy of your choice. Felix has indicated it expects its pricing to move dynamically as market pricing changes.

This matters because Canadian telehealth pricing has historically been opaque. Felix lays its pricing out up front: medication starting at $149/month, including delivery and for a limited time, a $0 initial assessment, with a $40 renewal consultation fee approximately every 3 months for ongoing clinical care. No surprises, and no obligation to continue.

Starting with Apotex - but Not Exclusively

Felix is launching with Apo-Semaglutide Injection, the generic from Apotex which Health Canada approved on May 1, 2026. Apotex is a Canadian company headquartered in North York, Ontario.

It is not an exclusive partnership. Felix is starting with Apotex because Apotex priced their generic the lowest among current entrants, and because of the Canadian-company alignment. Felix may adjust supplier decisions as the market evolves, based on price, availability, supply reliability, quality, and what is in patients' best interest.

“This decision will probably be fluid as the market changes - as products change, as availability changes, as price changes. Depending on what's in the best interest of the patient - that's what we do.” - From Sources

How Low Can Pricing Go?

The biggest question on every Canadian's mind right now: how low does this go? In some markets - India, for example - generic semaglutide has reached single-digit dollar pricing per month. When pressed directly on how low Canadian pricing could realistically go, the answer from sources was candid:

“I'm sure everyone would love eight dollars, but I think it's really difficult to predict. We're going to have to wait and see what happens. As more providers enter the market, things will change dynamically.”- From Sources

Read between the lines: even Felix does not know. Broader pricing pressure could extend beyond semaglutide to other medications in the category, as manufacturers evaluate how to compete in a changing market. As sources put it:

“You can imagine product managers having conversations in board rooms about what this is going to look like for them three months from now, six months from now.”- From Sources

The Market Is Not Done Moving

Felix is not the only Canadian telehealth platform offering Apotex's generic. Other telehealth providers have also confirmed access. More telehealth pricing announcements are likely in the coming weeks.

Health Canada currently has seven additional generic semaglutide submissions under review. Each new approval increases competition and adds further downward pressure on price. The pan-Canadian Pharmaceutical Alliance framework mandates price drops to 35% of brand price once three or more generics are competing - which, at current Ozempic list prices, would put generic semaglutide below $120/month in the public drug market.

The market is moving fast. If you have been waiting to start treatment because of cost, the barrier has fallen significantly. And it will likely fall further.